JPRN-UMIN000010855已完成2 期
Randomized phase II trial to evaluate the effectiveness of azacitidine for low risk MDS. - Randomized phase II trial to evaluate the effectiveness of azacitidine for low risk MDS.
ational Research Group on Idiopathic Bone Marrow Failure Syndromes0 个研究点目标入组 100 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Cases with scheduled hematopoietic stem cell transplantation. We do not exclude patients who are judged as transplant candidate after entry of this study because of change of medical conditions. 2)Cases who received hematopoietic stem cell transplantation. 3)Cases who had already been enrolled into other clinical trials for MDS. 4)Cases with pregnancy, possibility of pregnancy, in breast-feeding, or with plant to bear a child 5)Cases with hypersensitivity to azacitidine. 6)Cases with other cancers than MDS that is invasive within 5 years. 7)Cases with complicating diseases that are severe or uncontrolled. 8)Cases with psychiatric diseases or psychiatric symptoms that preclude adequate entry to the study. 9)Cases with cognitive disorders. 10)Patients who are receiving successful treatment with other modalities, or who are expected to achieve better response with other treatments (such as with 5q- syndrome). 11)Cases that are considered to be inadequate to enroll this study by the attending physicians.
研究者
相似试验
尚未招募
不适用
Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab plus capecitabine Adjuvant Therapy compared to Capecitabine monotherapy for Triple Receptor-Negative Breast Cancer with Residual Invasive Cancer after Neoadjuvant ChemotherapyNeoplasmsKCT0003426CC Hospital284
进行中（未招募）
1 期
Study to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA.ocalised Colon Cancer (stage II-III)MedDRA version: 21.0Level: PTClassification code 10009954Term: Colon cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10009955Term: Colon cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000507-20-ESInstituto de Investigación Sanitaria INCLIVA164
进行中（未招募）
不适用
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancerMetastatic breast cancerEUCTR2005-005581-36-ATSchering AG72
进行中（未招募）
不适用
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancermetastatic breast cancerEUCTR2005-005581-36-ITSCHERING72
进行中（未招募）
不适用
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMetastatic breast cancerEUCTR2005-005581-36-DEBayer Schering Pharma AG72